Kriya Announces Publication of Preclinical Data for Its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
UF Startup Kriya Therapeutics, a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the publication of preclinical data for its investigational AAV-FGF21 gene therapy.
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
UF Startup Kriya Therapeutics, a biopharmaceutical company developing gene therapies, announced preclinical data from its gene therapy program for thyroid eye disease (TED).
Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer
UF startup Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the appointment of J. Fraser Wright, Ph.D., to the position of chief gene therapy officer.
Fresh off Raising $150M, Durham Gene Therapy Startup Kriya Acquires Spain-Based Company
Kriya Therapeutics Inc., with dual headquarters in Durham and Palo Alto, Calif., has acquired a gene therapy startup that Kriya says will align with its approach to treating metabolic disease.
